Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D62LZO
|
|||
| Drug Name |
AR882
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Gout [ICD-11: FA25; ICD-10: M10] | Phase 2 | [1] | |
| Company |
Arthrosi Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Urate anion exchanger 1 (URAT1) | Target Info | Inhibitor | [2] |
| WikiPathways | Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04155918) A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of AR882 Administered Alone or in Combination With Febuxostat or Allopurinol in Gout Patients. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Arthrosi Therapeutics | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.